Lupron
(leuprolide acetate)Phase 3Small molecule
Leuprolide acetate is used to treat advanced prostate cancer by lowering testosterone levels, and it's also used to treat endometriosis and uterine fibroids in women by temporarily stopping the release of certain hormones.[1] Lupron is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Lupron is one of 252 small molecule programs targeting Bulbospinal Muscular Atrophy. It is currently in Phase 3.
17
Indications
113
Total Trials
20
Active Trials
251
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lupron
EEastern Cooperative Oncology Group
Phase 3
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Combination NRT
UUniversity of Alabama at Birmingham
Preclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Maxigesic
YYonsei University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer53 trials
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Completed·—·Phase 2·NCT02770391·54 enrolled
Show 50 more trials
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Terminated·—·Phase 2·NCT03093272·9 enrolled
Management of Castration-Resistant Prostate Cancer with Oligometastases
Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2/3·NCT02685397·102 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02716974·26 enrolled
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Recruiting·—·Phase 2·NCT04734730·70 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03043807·26 enrolled
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Withdrawn·—·Phase 2·NCT00003517
Metastatic Prostate Cancer9 trials
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled
Show 6 more trials
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT00544830·29 enrolled
Breast Cancer5 trials
Central precocious puberty3 trials
Prostate Adenocarcinoma3 trials
37 more indications
Alzheimer's Disease2 trials
Radiotherapy2 trials
Androgen Deprivation Therapy2 trials
Cognition1 trial
Randomized1 trial
Testosterone1 trial
Hematopoietic Stem Cell Transplantation1 trial
Uterine leiomyoma1 trial
Prostate1 trial
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Completed·—·Phase 2·NCT02268175·75 enrolled
Leiomyoma1 trial
Menopausal Women1 trial
Cystic1 trial
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
Unknown status·—·Phase 4·NCT04094467·150 enrolled
Postpartum Depression1 trial
High Risk1 trial
Post-operative or Early Salvage XRT and ADT for High Risk PCa
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00949962·87 enrolled
Acanthosis Nigricans1 trial
Polycystic Ovarian Syndrome (PCOS)1 trial
Lupron1 trial
Lupron Sex Offender Therapy
Unknown status·—·Phase 2/3·NCT00220350·10 enrolled
Outcome1 trial
The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
Unknown status·ZZekai Tahir Burak Women's Health Research and Education Hospital·N/A·NCT02114645·100 enrolled
Castration-Resistant Prostate Carcinoma1 trial
Locally Advanced Salivary Gland Carcinoma1 trial
Adult Ovarian Granulosa Cell Tumor1 trial
Prostate Carcinoma1 trial
Hypogonadotropic Hypogonadism1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for leuprolide acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details